Catalyst Wire Dossier Catalyst Wire Dossier

cerdulatinib

cerdulatinib · Portola Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for cerdulatinib, covering 2023-02-21 to 2023-02-21. Get the full timeline:

Most recent: Clinical Trial Update: CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) [Phase 2, Phase 3]

See pricing